Working… Menu

A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03352453
Recruitment Status : Terminated (Study stopped due to business reasons.)
First Posted : November 24, 2017
Last Update Posted : July 19, 2019
Information provided by (Responsible Party):
Naurex, Inc, an affiliate of Allergan plc

Brief Summary:
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) of Rapastinel, compared to placebo in adult patients with major depressive disorder (MDD) who are at imminent risk of suicide.

Condition or disease Intervention/treatment Phase
Depressive Disorder, Major Drug: Rapastinel Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 138 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients With Major Depressive Disorder
Actual Study Start Date : December 5, 2017
Actual Primary Completion Date : June 17, 2019
Actual Study Completion Date : June 17, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Rapastinel 450mg
Rapastinel 450 milligram (mg) weekly intravenous (IV) injections.
Drug: Rapastinel
Rapastinel pre-filled syringes for weekly IV injections.

Placebo Comparator: Placebo
Placebo-matching rapastinel weekly IV injections.
Drug: Placebo
Placebo-matching rapastinel pre-filled syringes for weekly IV injections.

Primary Outcome Measures :
  1. Change from baseline in Montgomery-Asberg Depression Rating Scale) MADRS Total Score [ Time Frame: Baseline and 1 Day ]
    The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and a lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change score indicates improvement.

Secondary Outcome Measures :
  1. Change from Baseline in Sheehan - Suicidality Tracking Scale (S-STS) Total Score [ Time Frame: Baseline and 1 Day ]
    The S-STS is a patient-report informed, clinician-rated scale used to rate the severity of suicidal impulses, thoughts, and behaviors. The scale is compatible with the FDA categories for prospective assessment of suicidal ideation and behavior. Developed for use as both a safety and efficacy outcome measure in research and in clinical settings, the scale is sensitive enough to detect an efficacy signal in conventional sample sizes used in clinical trials.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Meet Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5) criteria for MDD
  • Current major Depressive episode of at least 4 weeks and not exceeding 24 months in duration at visit 1
  • Have current, ongoing suicidality (ideation or behavior) of sufficient severity to warrant hospitalization based on the judgment of the investigator
  • If female of childbearing potential, have a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test.

Exclusion Criteria:

  • DSM-5-based diagnosis of any disorder other than MDD that was the primary focus of treatment within 1 month before Visit 1.
  • Lifetime history or currently meet DSM-5 criteria for:

    1. Schizophrenia spectrum or other psychotic disorder
    2. Bipolar or related disorder
    3. Major neurocognitive disorder
    4. Neurodevelopmental disorder of greater than mild severity or of a severity that impacts the participant's ability to consent, follow study directions, or otherwise safely participate in the study.
    5. Dissociative disorder
    6. Posttraumatic stress disorder
    7. MDD with psychotic features
  • Significant homicidal ideation or at imminent risk of injuring others or causing significant damage to property, as judged by the investigator.
  • Prior participation in any investigational study of rapastinel/GLYX-13

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03352453

Layout table for location information
United States, Alabama
The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294-0107
United States, California
Collaborative NeuroScience Network, LLC
Garden Grove, California, United States, 92845
Behavioral Research Specialists, LLC
Glendale, California, United States, 91206-4282
Asclepes Research Centers
Panorama City, California, United States, 91402
United States, Connecticut
Institute of Living
Hartford, Connecticut, United States, 06106
United States, Florida
Innovative Clinical Research, Inc
Hialeah, Florida, United States, 33012
Research Centers of America, LLC
Oakland Park, Florida, United States, 33334
United States, Georgia
Atlanta Center for Medical Research (ACMR)
Atlanta, Georgia, United States, 30331
United States, Illinois
Alexian Brothers Center for Psychiatric Research
Hoffman Estates, Illinois, United States, 60169
United States, Louisiana
Lake Charles Clinical Trials
Lake Charles, Louisiana, United States, 70629
United States, Maryland
CBH Health
Gaithersburg, Maryland, United States, 20877
United States, Nevada
Altea Research Institute
Las Vegas, Nevada, United States, 89102
United States, New York
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
United States, Ohio
Cincinnati VA Medical Center
Cincinnati, Ohio, United States, 45220-2288
United States, Texas
Pillar Clinical Research, LLC
Richardson, Texas, United States, 75080
United States, Virginia
Carilion Medical Center, a Virginia Nonprofit Corporation
Roanoke, Virginia, United States, 24014-2419
Department of Veterans Affairs Salem VA Medical Center
Salem, Virginia, United States, 24153
Sponsors and Collaborators
Naurex, Inc, an affiliate of Allergan plc
Layout table for investigator information
Study Director: Jenna Hoogerheyde Allergan

Additional Information:
Layout table for additonal information
Responsible Party: Naurex, Inc, an affiliate of Allergan plc Identifier: NCT03352453     History of Changes
Other Study ID Numbers: RAP-MD-20
First Posted: November 24, 2017    Key Record Dates
Last Update Posted: July 19, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Depressive Disorder, Major
Pathologic Processes
Behavioral Symptoms
Mood Disorders
Mental Disorders